Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 264 Show results per page	View Search Criteria \| Help With Results


1.		EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				EGF103659 NCT00338247

Last Modified: 4/2/2008 First Published: 1/25/2007


2.		Phase IV Randomized Study of Doxorubicin Hydrochloride Liposome Versus Capecitabine as First-Line Chemotherapy in Women With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				SPRI-P04445 EU-20654, NCT00266799, SPRI-PELICAN


3.		Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Approved-not yet active				18 to 70				Other				GEICAM/2005-01 NCT00434941


4.		A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				ML20592 NCT00502671

First Published: 11/14/2007


5.		Phase IV Study of Chemoresistance Markers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				CHUL-BIO-COLON RECF0356, INCA-RECF0356, NCT00559676


6.		OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				ML21380 NCT00577031

Last Modified: 1/4/2007 First Published: 10/24/2006


7.		Phase II/III Study of Neoadjuvant Therapy Comprising Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) (Abraxane®) in Women With Previously Untreated, Unresected, Stage II-IIIB Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				WHC-MRI-GU-2006-097 NCT00397761


8.		Standard Versus Continuous Capecitabine in Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 75				Other				05/237 NCT00418028

Last Modified: 6/24/2008 First Published: 3/16/2007


9.		Phase II/III Randomized Study of Neoadjuvant and Adjuvant Chemotherapy Comprising Epirubicin Hydrochloride, Cisplatin, and Capecitabine With or Without Bevacizumab in Patients With Previously Untreated, Resectable Gastric or Gastroesophageal Junction Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				MRC-ST03 EU-20710, ISRCTN46020948, EUDRACT-2006-000811-12, CTA-00316/0221/001, NCT00450203

Last Modified: 2/27/2008 First Published: 7/24/2007


10.		Phase II/III Randomized Study of Chemoradiotherapy Comprising Cisplatin, Capecitabine, and Radiotherapy With or Without Cetuximab in Patients With Carcinoma of the Esophagus

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				WCTU-SCOPE-1 EU-20739, EUDRACT-2006-002241-37, ISRCTN47718479, CTA-17853/0202/001-0001, NCT00509561

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute